23:04 , Jan 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer Mouse studies suggest a photo-activated imiquimod-loaded nanoparticle could help treat cancer. The nanoparticle consisted of poly(lactic-co-glycolic) acid (PLGA) loaded with indocyanine green, a dye that generates tumor cell-killing heat when exposed to near-infrared...
08:00 , Jan 9, 2014 |  BC Innovations  |  Cover Story

Light it up

Poor tumor definition is a central challenge in cancer surgery, which aims to remove all malignant cells while preserving normal tissue. Now, a team from The University of Texas Southwestern Medical Center has designed fluorescent...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Clinical News

Zybrestat fosbretabulin: Additional Phase II data

Additional data from the double-blind, Asian Phase II FAVOR trial in 20 patients with PCV showed that a single IV injection of 15 mg/kg Zybrestat led to a "transient" reduction in polyp activity as measured...
08:00 , Feb 27, 2012 |  BC Week In Review  |  Clinical News

Diagnogreen indocyanine green regulatory update

Japan's Ministry of Health, Labor and Welfare (MHLW) approved an sNDA for Diagnogreen indocyanine green IV injection for near-infrared fluorescence angiography during cerebrovascular surgery. Japan's Pharmaceutical Affairs and Food Sanitation Council met last July and...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Clinical News

Zybrestat fosbretabulin: Phase II data

OxiGene reported data from the double-blind, placebo-controlled, Asian Phase II FAVOR trial in 20 patients with PCV showing that a single IV injection of Zybrestat led to "essentially" no change in the number of polyps...
07:00 , Jun 29, 2009 |  BC Week In Review  |  Clinical News

Fosbretabulin: Phase II started

Oxigene began the double-blind, placebo-controlled, Asian Phase II FAVOR trial to evaluate 4 dosages of IV Zybrestat in about 40 patients. OxiGene Inc. (NASDAQ:OXGN; SSE:OXGN), Waltham, Mass.   Product: Fosbretabulin ( Combretastatin A4P , Zybrestat...
07:00 , Apr 28, 1997 |  BC Week In Review  |  Clinical News

Xytronyx preclinical data

XYX published results in Cancer Letters showing that local treatment of mammary tumors in rats by PDIT led to an immune response that destroyed both local and metastatic cancer cells. PDIT involves co-injection of an...